These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 15886320

  • 1. Altered NKG2D function in NK cells induced by chronic exposure to NKG2D ligand-expressing tumor cells.
    Coudert JD, Zimmer J, Tomasello E, Cebecauer M, Colonna M, Vivier E, Held W.
    Blood; 2005 Sep 01; 106(5):1711-7. PubMed ID: 15886320
    [Abstract] [Full Text] [Related]

  • 2. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways.
    Coudert JD, Scarpellino L, Gros F, Vivier E, Held W.
    Blood; 2008 Apr 01; 111(7):3571-8. PubMed ID: 18198346
    [Abstract] [Full Text] [Related]

  • 3. Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.
    Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM.
    J Immunol; 2003 Dec 15; 171(12):6891-9. PubMed ID: 14662896
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin.
    Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S, Nanni M, Biassoni R, Bottino C, Moretta A, Moretta L.
    Eur J Immunol; 2001 Apr 15; 31(4):1076-86. PubMed ID: 11298332
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
    Wiemann K, Mittrücker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A.
    J Immunol; 2005 Jul 15; 175(2):720-9. PubMed ID: 16002667
    [Abstract] [Full Text] [Related]

  • 8. Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
    André P, Castriconi R, Espéli M, Anfossi N, Juarez T, Hue S, Conway H, Romagné F, Dondero A, Nanni M, Caillat-Zucman S, Raulet DH, Bottino C, Vivier E, Moretta A, Paul P.
    Eur J Immunol; 2004 Apr 15; 34(4):961-71. PubMed ID: 15048706
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Immunoediting of natural killer cells by human nasopharyngeal carcinoma cell line: altered expression of KIRs and NKG2D receptors leads to reduction of natural killer cell-mediated cytolysis].
    Guo KY, Mei JZ, Yao KT.
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Mar 15; 27(3):247-9. PubMed ID: 17425963
    [Abstract] [Full Text] [Related]

  • 11. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
    Zhang T, Lemoi BA, Sentman CL.
    Blood; 2005 Sep 01; 106(5):1544-51. PubMed ID: 15890688
    [Abstract] [Full Text] [Related]

  • 12. "Acquired" NKG2D Ligand Stimulates NK Cell-mediated Tumor Immunosurveillance.
    Wang D, Gu X, Liu X, Liu X, Wang B, Lao F, Fang M.
    J Immunother; 2019 Sep 01; 42(6):189-196. PubMed ID: 31145234
    [Abstract] [Full Text] [Related]

  • 13. Costimulation of multiple NK cell activation receptors by NKG2D.
    Ho EL, Carayannopoulos LN, Poursine-Laurent J, Kinder J, Plougastel B, Smith HR, Yokoyama WM.
    J Immunol; 2002 Oct 01; 169(7):3667-75. PubMed ID: 12244159
    [Abstract] [Full Text] [Related]

  • 14. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
    Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T.
    Science; 1999 Jul 30; 285(5428):727-9. PubMed ID: 10426993
    [Abstract] [Full Text] [Related]

  • 15. Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104.
    Brando C, Mukhopadhyay S, Kovacs E, Medina R, Patel P, Catina TL, Campbell KS, Santoli D.
    J Leukoc Biol; 2005 Aug 30; 78(2):359-71. PubMed ID: 15937142
    [Abstract] [Full Text] [Related]

  • 16. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.
    Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC.
    Nat Immunol; 2005 Sep 30; 6(9):928-37. PubMed ID: 16116470
    [Abstract] [Full Text] [Related]

  • 17. Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation.
    Malarkannan S, Regunathan J, Chu H, Kutlesa S, Chen Y, Zeng H, Wen R, Wang D.
    J Immunol; 2007 Sep 15; 179(6):3752-62. PubMed ID: 17785812
    [Abstract] [Full Text] [Related]

  • 18. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
    Zhang C, Zhang J, Niu J, Zhou Z, Zhang J, Tian Z.
    Hum Immunol; 2008 Aug 15; 69(8):490-500. PubMed ID: 18619507
    [Abstract] [Full Text] [Related]

  • 19. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
    Schwinn N, Vokhminova D, Sucker A, Textor S, Striegel S, Moll I, Nausch N, Tuettenberg J, Steinle A, Cerwenka A, Schadendorf D, Paschen A.
    Int J Cancer; 2009 Apr 01; 124(7):1594-604. PubMed ID: 19089914
    [Abstract] [Full Text] [Related]

  • 20. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
    Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D.
    Blood; 2006 Aug 15; 108(4):1313-9. PubMed ID: 16621962
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.